The development and application of imatinib

Expert Opinion on Drug Safety

Volumn 4, Issue 2, 2005, Pages 183-191

  Jones, Robin L ^a   Judson, Ian R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia (CML); Gastrointestinal stromal tumour (GIST); Imatinib; Tyrosine kinase inhibition

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOGENETICS; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; EXFOLIATIVE DERMATITIS; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROSCOPY; GENE MUTATION; HUMAN; KIDNEY FAILURE; LEUKEMIA RELAPSE; LIVER TOXICITY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; ONCOGENE C KIT; PANCYTOPENIA; PROGNOSIS; REVIEW; STOMACH BIOPSY; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; DERMATOFIBROSARCOMA; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 20944444824     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.2.183     Document Type: Review

References (76)

1. HANNAHAN D, WEINBERG RA: The hallmarks of cancer. Cell. (2000) 100:57-70.
2. SCHER HI, SARKIS A, REUTER V et al.: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin. Cancer Res. (1995) 1:545-550.
3. MCLENDON RE, WIKSTRAND CJ, MATTHEWS MR et al.: Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor. J Histochem. Cytochem. (2000) 48:1103-1110.
4. FONTANINI G, DELAURENTIIS M, VIGNATI S et al.: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. (1998) 4:241-249.
5. GRANDIS JR, MELHEM MF, GOODING WE et al.: Levels of TGF-alpha and EFGr protein in head and neck squamous cell carcinoma and patient survival. J Natl. Cancer Inst. (1998) 90:824-832.
6. SPRITZ RA, STRUNK KM, LEE ST et al.: A YAC contig spanning a cluster of human Type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics (1994) 22:431-436.
7. VAN ETTEN RA, JACKSON P, BALTIMORE D: The mouse Type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell (1989) 58(4):669-678.
8. DRUKER BJ, LYDON NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia. J. Clin. Invest. (2000) 105:3-7.
9. ANAFI M, GAZIT A, GILON C, BEN-NERIAH Y, LEVITZKI A: Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates and tyrphostins. J. Biol. Chem. (1992) 267(7):4518-4523.
10. BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56:100-104.
11. CARROLL M, OHNO-JONES S, TAMURA S et al.: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-Abl, TEL-Abl and TEL-PDGFR fusion proteins. Blood (1997) 90:4947-4952.
12. FADERL S, TALPAZ M, ESTROV Z et al.: The biology of chronic myeloid leukaemia. N. Engl. J. Med. (1999) 341:164-172.
13. SAWYERS CL: Chronic myeloid leukaemia. N. Engl. J. Med. (1999) 340:1330-1340.
14. NOWELL PC, HUNGERFORD DA: A minute chromosome in human chronic granulocytic leukaemia. Science (1960) 132:1497-1501.
15. ROWLEY JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243:290-293.
16. KALIDAS M, KANTARJIAN H, TALPAZ M: Chronic myelogenous leukaemia. JAMA (2001) 286:895-898.
17. DEININGER MW, GOLDMAN JM, LYNDON N, MELO JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood (1997) 90:3691-3698.
18. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-Abl tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. (2001) 344:1031-1037.
19. KANTARJIAN H, SAWYERS C, HOCHHAUS A et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N. Engl. J. Med. (2002) 346:645-652.
20. O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. (2003) 348:994-1004.
21. CORTES J, GILES F, O'BRIEN S et al.: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukaemia after failure of interferon-α. Blood (2003) 102:83-86.
22. KANTARJIAN H, TALPAZ M, O'BRIEN S et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood (2004) 103:2873-2878.
23. TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukaemia: results of a Phase II study. Blood (2002) 99:1928-1937.
24. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-Abl tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042.
25. SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99:3530-3539.
26. KANTARJIAN HM, CORTES J, O'BRIEN S et al.: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukaemia in blast phase. Blood (2002) 99:3547-3553.
27. DEININGER MW, DRUKER BJ: Specific targeted therapy of chronic myelogenous leukaemia with imatinib. Pharmacol. Rev. (2003) 55:401-423.
28. BERGER U, ENGELICH G, REITER A, HOCHHAUS A, HEHLMANN R AND THE GERMAN CML STUDY GROUP: Imatinib and beyond - The new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Ann. Haematol. (2004) 83:258-264.
29. DEMATTEO RP, LEWIS JJ, LEUNG D, MUDAN SS, WOODRUFF JM, BRENNAN MF: Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann. Surg. (2000) 231:51-58.
30. KINDBLOM L-G, REMOTTI HE, ALDENBORG F, MEIS-KINDBLOM JM: Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. (1998) 152:1259-1269.
31. GRAADT VAN ROGGEN JF, VAN VELTHUYSEN ML, HOGENDOORN PC: The histopathological differential diagnosis of gastrointestinal stromal tumours. J. Clin. Pathol. (2001) 54:96-102.
32. RUMESSEN JJ, PETERS S, THUNEBERG L: Light- and electron microscopical studies of interstitial cells of Cajal and muscle cells at the submucosal border of human colon. Lab. Investig. (1993) 68:481-495.
33. MIETTINEN M, LASOTA J: Gastrointestinal stromal tumours - definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch. (2001) 438:1-12.
34. MIETTINEN M, SOBIN LH, SARLOMO-RIKALA M: Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod. Pathol. (2000) 13:1134-1142.
35. MIETTINEN M, SARLOMO-RIKALA M, LASOTA J: Gastrointestinal stromal tumours: recent advances in understanding of their biology. Hum. Pathol. (1999) 30:1213-1220.
36. FLETCHER CDM, BERMAN JJ, CORLESS C et al.: Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum. Pathol. (2002) 33:459-465.
37. HEINRICH MC, GRIFFITH DJ, DRUKER BJ, WAIT CL, OTT KA, ZIGLER AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 96:925-932.
38. HEINRICH MC, RUBIN BP, LONGLEY BJ, FLETCHER JA: Biology and genetic aspects of gastrointestinal stromal tumours: KIT activation and cytogenetic alterations. Hum. Pathol. (2002) 33:484-495.
39. BAUER S, CORLESS CL, HEINRICH MC: Response to imatinib mesylate of a gastrointestinal stromal tumour with very low expression of KIT. Cancer Chemother. Pharmacol. (2003) 51:261-265.
40. SABAH M, LEADER M, KAY E: The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl. Immunohistochem. Molec. Morphol. (2003) 11:56-61.
41. ROBERTS PJ, EISENBERG B: Clinical presentation of gastrointestinal stromal tumours and treatment of operable disease. Eur. J. Cancer (2002) 38:S37-S38.
42. HEINRICH MC, BLAKE CD, DRUKER BJ, CORLESS CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. (2002) 20:1692-1703.
43. JUDSON I: Gastrointestinal stromal tumours (GIST): biology and treatment. Ann. Oncol. (2002) 13:287-289.
44. RUBIN BP, SINGER S, TSAO C et al.: KIT activation is a ubiquitous feature of gastrointestinal stromal tumours. Cancer Res. (2001) 61:8118-8121.
45. CORLESS CL, FLETCHER JA, HEINRICH MC: Biology of Gastrointestinal Stromal Tumours. J. Clin. Oncol. (2004) 22:3813-3825.
46. HIROTA S, ISOZAKI K, MORIYAMA Y et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science (1998) 279:577-580.
47. SINGER S, RUBIN BP, LUX ML et al.: Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal tumours. J. Clin. Oncol. (2002) 20:3898-3905.
48. LASOTA J, JASINSKI M, SARLOMO-RIKALA M et al.: Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leimyosarcomas. Am. J. Pathol. (1999) 154:53-60.
49. ERNST SI, HUBBS AE, PRZYGODZKI RM et al.: KIT mutations portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab. Invest. (1998) 78:1633-1636.
50. LI SQ, O'LEARY TJ, SOBIN LH et al.: Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytol. (2000) 44:981-986.
51. MOSKALUK CA, TIAN Q, MARSHALL CR et al.: Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene (1999) 18:1897-1902.
52. TANIGUCHI M, NISHIDA T, HIROTA S et al.: Effect of c-kit mutation on prognosis of gastrointescinal stromal tumors. Cancer Res. (1999) 59:4297-4300.
53. LUX ML, RUBIN BP, BIASE TL et al.: KIT extracellutar and kinase domain mutations in gastrointestinal stromal tumours. Am. J. Pathol. (2000) 156:791-795.
54. VAN OOSTEROM A, JUDSON I, VERWEIJ J et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421-1423.
55. VERWEIJ J, VAN OOSTEROM A, BLAY J-Y et al.: Imatinib mesylate (STI-571, Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue bone Sarcoma Group Phase II study. Eur. J. Cancer (2003) 39:2006-2011.
56. DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N. Engl. J. Med. (2002) 347:472-480.
57. VERWEIJ J, CASALI PG, ZALCBERG J et al.: Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumours (GIST): Interim results of a randomised Phase III trial from the EORTC-STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. (2003) 814:abstract 3272.
58. BENJAMIN RS, RANKIN C, FLETCHER C et al.: Phase III dose-randomized study of imatinib mesylate (STI571) for GIST. Intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol. (2003) 814:abstract 3271.
59. VERWEIJ J, CASALI P, ZALCBERG J et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 364:1127-1134.
60. HEINRICH MC, CORLESS CL, DUENSING A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 299:708-710.
61. HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J. Clin. Oncol. (2003) 23:4342-4349.
62. DEBIEC-RYCHTER M, DUMEZ H, JUDSON I et al.: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered into Phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer (2004) 40:689-695.
63. MAKI RG, AWAN RA, DIXON RH, JHANWAR S, ANTONESCU CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer (2002) 100(6):623-626.
64. APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. (2002) 347(7):481-487.
65. GLEICH GJ, LEIFERMAN KM, PARDANANI A, TEFFERI A, BUTTERFIELD JH: Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (2002) 359:1577-1578.
66. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
67. HOCHHAUS A, KRIEL S, CORBIN A et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukaemia (2002) 16:2190-2196.
68. HOCHHAUS A, KRIEL S, CORBIN A et al.: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293:2163a.
69. BARTHE C, CONY-MAKHOUL P, MELO JV, REIFFERS J, MAHON FX: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293:2163a.
70. BRANFORD S, RUDZKI Z, WALSH S et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukaemia who develop imatinib (STI571) resistance. Blood (2002) 99:3472-3475.
71. VON BUBNOFF N, SCHNELLER F, PESCHEL C, DUYSTER J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI-571: a prospective study. Lancet (2002) 359:487-491.
72. SHAH NP, NICOLL JM, GORRE ME, PAQUETTE RL, FORD J, SAWYERS CL: Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo- resistant cases of chronic myelogenous leukaemia (CML) in myeloid blast crisis. Blood (2001) 98(suppl. 1):770a.
73. DOREY K, ENGEN JR, KRETZSCHMAR J et al.: Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene (2001) 20:8075-8084.
74. DAUB H, SPECHT K, ULLRICH A: Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. (2004) 3: 1001-1010.
75. BRANFORD S, RUDZKI Z, WALSH S et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 102:276-283.
76. LA ROSÉE P, O'DWYER ME, DRUKER BJ: Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukaemia: a translational perspective. Leukaemia (2002) 16:1213-1219.